




Searching News Database: Radiation Syndrome
HSMN NewsFeed - 20 Nov 2023
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
HSMN NewsFeed - 21 Oct 2013
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
HSMN NewsFeed - 3 Oct 2013
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 13 Feb 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
HSMN NewsFeed - 2 Jun 2011
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
HSMN NewsFeed - 12 Feb 2009
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
HSMN NewsFeed - 15 Jan 2009
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
HSMN NewsFeed - 15 Jan 2009
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
HSMN NewsFeed - 8 May 2008
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
HSMN NewsFeed - 7 Jan 2008
Osiris Therapeutics Regains Worldwide Rights to Cardiovascular Indications for Prochymal(TM)
Osiris Therapeutics Regains Worldwide Rights to Cardiovascular Indications for Prochymal(TM)
HSMN NewsFeed - 11 Jan 2007
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
HSMN NewsFeed - 26 Oct 2006
Cleveland BioLabs President and CEO Provides Update on Clinical and Corporate Developments
Cleveland BioLabs President and CEO Provides Update on Clinical and Corporate Developments
Additional items found! 4

Members Archive contains
4 additional stories matching:
Radiation Syndrome
(Password required)
Radiation Syndrome
(Password required)